Dominique Verhelle
Publications by Year
Research Areas
Protein Degradation and Inhibitors, Histone Deacetylase Inhibitors Research, Multiple Myeloma Research and Treatments, Epigenetics and DNA Methylation, Chromatin Remodeling and Cancer
Most-Cited Works
- → The SMARCA2/4 ATPase Domain Surpasses the Bromodomain as a Drug Target in SWI/SNF-Mutant Cancers: Insights from cDNA Rescue and PFI-3 Inhibitor Studies(2015)268 cited
- → Lenalidomide and CC-4047 Inhibit the Proliferation of Malignant B Cells while Expanding Normal CD34+ Progenitor Cells(2007)231 cited
- → Pomalidomide and lenalidomide regulate erythropoiesis and fetal hemoglobin production in human CD34+ cells(2008)178 cited
- → Pomalidomide and Lenalidomide Induce p21WAF-1 Expression in Both Lymphoma and Multiple Myeloma through a LSD1-Mediated Epigenetic Mechanism(2009)170 cited
- → Optimization of Orally Bioavailable Enhancer of Zeste Homolog 2 (EZH2) Inhibitors Using Ligand and Property-Based Design Strategies: Identification of Development Candidate (R)-5,8-Dichloro-7-(methoxy(oxetan-3-yl)methyl)-2-((4-methoxy-6-methyl-2-oxo-1,2-dihydropyridin-3-yl)methyl)-3,4-dihydroisoquinolin-1(2H)-one (PF-06821497)(2017)126 cited
- → Design and Synthesis of Pyridone-Containing 3,4-Dihydroisoquinoline-1(2 H )-ones as a Novel Class of Enhancer of Zeste Homolog 2 (EZH2) Inhibitors(2016)68 cited
- → Preclinical target validation using patient-derived cells(2015)53 cited
- → Epigenetic reprogramming by tumor-derived EZH2 gain-of-function mutations promotes aggressive 3D cell morphologies and enhances melanoma tumor growth(2015)45 cited
- → Immunomodulatory Drug CC-4047 is a Cell-type and Stimulus-Selective Transcriptional Inhibitor of Cyclooxygenase 2(2007)32 cited
- → Differential Repression ofc-mycandcdc2Gene Expression by ERF and PE-1/METS(2007)15 cited